Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 86 clinical trials
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

  • 37 views
  • 27 Sep, 2021
  • 278 locations
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. …

stage iii breast cancer
epirubicin
trastuzumab
HER2
fluorouracil
  • 33 views
  • 07 Nov, 2020
  • 1 location
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

The goal of this research is to test the accuracy of PET/MRI imaging with 18F-fluorofuranylnorprogesterone (FFNP) for measuring progesterone receptor (PR) expression in patients with invasive

progesterone
progesterone receptor
immunohistochemistry
  • 0 views
  • 04 Apr, 2021
  • 1 location
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or

triple-negative breast cancer
HER2
cyclophosphamide
platelet count
endocrine therapy
  • 0 views
  • 26 Sep, 2021
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

Basal like breast carcinoma is a Her2, estrogen receptor (ER) progesterone receptor (PR) negative breast cancer. It is notable for the high level of epidermal growth factor receptor (EGFR

carcinoma
progesterone
EGFR
paclitaxel
breast carcinoma
  • 2 views
  • 07 Nov, 2020
  • 1 location
Role of 200 mg Versus 400mg Vaginal Progesterone in Prevention of Preterm Labor in Twin Gestation

The objective of the present study is to evaluate the effectiveness of two doses of vaginal progesterone(200mg versus400mg) and placebo in improving gestational age in twin pregnancy and its subsequent impact on perinatal outcome.

  • 0 views
  • 23 Jan, 2021
  • 1 location
Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer

RATIONALE: Diagnostic procedures, such as breast duct endoscopy, may improve the ability to detect breast cancer earlier and plan more effective treatment. PURPOSE: This phase II trial is studying how well breast duct endoscopy works in assessing cellular atypia (abnormal cells) in the breast ducts of women with a genetic …

immunohistochemistry
  • 0 views
  • 07 Nov, 2020
  • 1 location
Nipple Aspiration Ductal Lavage and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer

RATIONALE: Diagnostic procedures, such as nipple aspiration, ductal lavage, and breast duct endoscopy, may help doctors detect and assess breast cancer cells early and plan more effective treatment. PURPOSE: This phase II trial is studying how well nipple aspiration, ductal lavage, and duct endoscopy work in assessing cancer cells in …

immunohistochemistry
  • 0 views
  • 07 Nov, 2020
  • 1 location
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients

  • 0 views
  • 26 Jan, 2021
  • 28 locations
Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

The primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).

  • 0 views
  • 11 Aug, 2021
  • 18 locations